Keywords
COVID-19, Complications, Bibliometry Analysis, Citations, SARS-COV-2
This article is included in the Manipal Academy of Higher Education gateway.
This bibliometric analysis examines the top 50 most-cited articles on COVID-19 complications, offering insights into the multifaceted impact of the virus. Since its emergence in Wuhan in December 2019, COVID-19 has evolved into a global health crisis, with over 770 million confirmed cases and 6.9 million deaths as of September 2023. Initially recognized as a respiratory illness causing pneumonia and ARDS, its diverse complications extend to cardiovascular, gastrointestinal, renal, hematological, neurological, endocrinological, ophthalmological, hepatobiliary, and dermatological systems.
Identifying the top 50 articles from a pool of 5940 in Scopus, the analysis spans November 2019 to July 2021, employing terms related to COVID-19 and complications. Rigorous review criteria excluded non-relevant studies, basic science research, and animal models. The authors independently reviewed articles, considering factors like title, citations, publication year, journal, impact factor, authors, study details, and patient demographics.
The focus is primarily on 2020 publications (96%), with all articles being open access. Leading journals include The Lancet, NEJM, and JAMA, with prominent contributions from Internal Medicine (46.9%) and Pulmonary Medicine (14.5%). China played a major role (34.9%), followed by France and Belgium. Clinical features were the primary study topic (68%), often utilizing retrospective designs (24%). Among 22,477 patients analyzed, 54.8% were male, with the most common age group being 26-65 years (63.2%). Complications of COVID-19 affected 13.9% of patients, with a recovery rate of 57.8%.
Analyzing these top-cited articles offers clinicians and researchers a comprehensive, timely understanding of influential COVID-19 literature. This approach uncovers attributes contributing to high citations and provides authors with valuable insights for crafting impactful research. As a strategic tool, this analysis facilitates staying updated and making meaningful contributions to the dynamic field of COVID-19 research.
COVID-19, Complications, Bibliometry Analysis, Citations, SARS-COV-2
In December 2019, the first outbreak of Coronavirus disease (COVID-19) was detected in Wuhan.1 On 30th January 2020, the World Health Organization (WHO) declared COVID-19 outbreak as a “public health emergency of international concern” and on 11th March 2020, COVID-19 was declared a pandemic by the WHO.2 As of September 2023, the coronavirus SARS-COV-2 (severe acute respiratory syndrome coronavirus-2) is responsible for a total of 770 million confirmed cases and 6.9 million confirmed deaths. With the start of COVID-19 vaccination, a total of 3 billion vaccine doses have been administered as per WHO.3 While, SARS-COV-2 is primarily considered as a respiratory disease known to cause pneumonia and acute respiratory distress syndrome (ARDS), there have been numerous reports about its many extra pulmonary manifestations. Literature suggests that the cardiovascular, gastrointestinal, renal, haematological, neurologic, endocrinologic, ophthalmologic, hepatobiliary and dermatologic systems can all be affected.4 This can result either due to the extrapulmonary dissemination and replication of the SARS-COV-2 or due to the widespread immunopathological sequelae of the disease.5
Bibliometric analysis is the application of statistical methods to evaluate the impact of a manuscript, research performance, author contribution to a particular field and to quantitatively analyse the most influential articles related to a particular field.6
According to our literature search, no current bibliometric analysis has focused on COVID-19 complications. The purpose of this bibliometric analysis was to compile and analyse the top 50 most-cited articles regarding COVID-19 complications across all peer-reviewed scientific journals.
A bibliometric analysis of the most cited articles about COVID-19 complications was conducted in July 2021 using all journals indexed in Elsevier’s Scopus and Thomas Reuter’s Web of Science from November 1, 2019 to July 1, 2021. All journals were selected for inclusion regardless of country of origin, language, medical speciality, or electronic availability of articles or abstracts. The terms were combined as follows:
(“COVID-19” OR “COVID19” OR “SARS-COV-2” OR “SARSCOV2” OR “SARS 2” OR “Novel coronavirus” OR “2019-nCov” OR “Coronavirus”)
AND
(“Complication” OR “Long Term Complication” OR “Post-Intensive Care Syndrome” OR “Venous Thromboembolism” OR “Acute Kidney Injury” OR “Acute Liver Injury” OR “Post COVID-19 Syndrome” OR “Acute Cardiac Injury” OR “Cardiac Arrest” OR “Stroke” OR “Embolism” OR “Septic Shock” OR “Disseminated Intravascular Coagulation” OR “Secondary Infection” OR “Blood Clots” OR “Cytokine Release Syndrome” OR “Paediatric Inflammatory Multisystem Syndrome” OR “Vaccine Induced Thrombosis with Thrombocytopenia Syndrome” OR “Aspergillosis” OR “Mucormycosis” OR “Autoimmune Thrombocytopenia Anaemia” OR “Immune Thrombocytopenia” OR “Subacute Thyroiditis” OR “Acute Respiratory Failure” OR “Acute Respiratory Distress Syndrome” OR “Pneumonia” OR “Subcutaneous Emphysema” OR “Pneumothorax” OR “Pneumomediastinum” OR “Encephalopathy” OR “Pancreatitis” OR “Chronic Fatigue” OR “Rhabdomyolysis” OR “Neurologic Complication” OR “Cardiovascular Complications” OR “Psychiatric Complication” OR “Respiratory Complication” OR “Cardiac Complication” OR “Vascular Complication” OR “Renal Complication” OR “Gastrointestinal Complication” OR “Haematological Complication” OR “Hepatobiliary Complication” OR “Musculoskeletal Complication” OR “Genitourinary Complication” OR “Otorhinolaryngology Complication” OR “Dermatological Complication” OR “Paediatric Complication” OR “Geriatric Complication” OR “Pregnancy Complication”) in the Title, Abstract or Keyword.
A total of 5940 articles were accessed, of which the top 50 most cited articles about COVID-19 and Complications of COVID-19 were selected through Scopus. Each article was reviewed for its appropriateness for inclusion. The articles were independently reviewed by three researchers (JRP, MAM and TS) (Table 1). Differences in opinion with regards to article inclusion was resolved by consensus.
The inclusion criteria specified articles that were focused on COVID-19 and Complications of COVID-19. Articles were excluded if they did not relate to COVID-19 and or complications of COVID-19, Basic Science Research and studies using animal models or phantoms. Review articles, Viewpoints, Guidelines, Perspectives and Meta-analysis were also excluded from the top 50 most-cited articles (Table 1).
The top 50 most-cited articles were compiled in a single database and the relevant data was extracted. The database included: Article Title, Scopus Citations, Year of Publication, Journal, Journal Impact Factor, Authors, Number of Authors, Department Affiliation, Number of Institutions, Country of Origin, Study Topic, Study Design, Sample Size, Open Access, Non-Original Articles, Patient/Participants Age, Gender, Symptoms, Signs, Co-morbidities, Complications, Imaging Modalities Used and outcome.
Of the total 50 articles that were analyzed, 48 (96%) articles were published in the year 2020, while 1 (2%) article was published in 2021 and 1 (2%) article was published in the year 2003 (Table 2).
All of the 50 (100%) articles analyzed in the bibliometric study were open access articles.
Of the total 50 articles that were analyzed, the journals that published the most number of articles published were in the The Lancet (9), NEJM (7) and JAMA (4), while Eurosurveillance, Transitional Research and Annals of Internal Medicine published one each (Table 3).
Among the 50 articles that were analyzed, the most frequently cited authors contributed 4 articles each to the list (Table 4).
Among the top 50 most-cited articles, the departmental affiliations were primarily in Internal Medicine (46.9%), Pulmonary Medicine (14.5%), and Bioscience and Technology (12.1%). Conversely, the Departments of Immunology, Paediatrics, and Urology had the lowest representation (Table 5).
In the research analyzed within the top 50 COVID-19 articles, a total of 83 countries participated. Notably, China played a substantial role, contributing to 29 articles (34.9%). France and Belgium closely followed; each being involved in 10 articles (12.1%). Additional contributing nations included Canada with 3 articles (3.6%), the UK with 2 articles (2.4%), and Switzerland with 1 article (1.2%) (Table 6).
Among the 50 most-cited articles examined in this analysis, the predominant research themes were clinical features, comprising 34 articles (68%). Following closely were articles related to drug trials and interactions, accounting for 6 articles (12%). Additionally, there were 3 articles (6%) dedicated to analytical studies. Mortality studies constituted 2 articles (4%), while a single article each (2%) delved into the psychological impact and molecular mechanisms of COVID-19 (Table 7).
Among the 50 most-cited articles examined, the most common study designs were retrospective (24%), followed by prospective (16%) and correspondence (12%). Other study designs included prospective cohort (4%), randomized controlled trial (4%), and cross-sectional (2%) (Table 8).
A total of 22477 patients were analyzed from the top 50 most-cited articles.
Of the total 22477 patients, 12318 (54.8%) were males while 10159 (45.2%) were females (Table 9).
The most common age group among the patients was 26-65 years of age with 14255 (63.2%) patients, followed by the age of 65 years with 6018 (26.8%) patients and then 12-25 years with 2204 (9.8%) patients (Table 10).
Among the 22477 patients, the most common clinical features were fever in 6333 (28.2%) patients, tachycardia in 4022 (17.9%) patients and dry cough in 3107 (13.8%) patients. Other common features included impaired sense of smell in 412 (1.8%) patients, impaired taste sensation in 404 (1.8%) patients and headache in 330 (1.5%) patients (Table 11).
A total of 22477 patients underwent RT-PCR testing and were positive for COVID-19. Out of which, 18055 (80.3) patients underwent additional laboratory investigations. CT-chest was done for 11110 (49.4%) patients, chest X-ray was done for 8327 (22.7%) patients, and ECG done for 5098 (22.7%) patients. MRI brain and EEG were done for 8 (0.04%) patients with neurological complications (Table 12).
Out of the total 22477 patients, 21989 (97.8%) patients were found to have comorbidities. Of the 21989 patients with comorbidities, hypertension was present in 6720 (30.6%) patients, diabetes mellitus in 5082 (23.1%) patients and obesity in 2666 (12.1%) patients. Other comorbidities found included chronic liver disease in 74 (0.34%) patients, endocrine disorders in 53 (0.24%) patients and psychiatric disorders in 13 (0.06%) patients (Table 13).
Out of the total 22477 patients, 3143 (13.9%) patients developed complications. The most common complication seen among the patients were acute kidney injury in 707 (22.5%) patients, ARDS in 576 (18.3%) patients and Sepsis in 347 (11.0%) patients. Other complications included electrolyte imbalance in 81 (2.6%) patients, acute hepatic injury in 74 (2.4%) patients and arrhythmias in 63 (2.0%) patients (Table 14).
Of the total 22477 patients who tested positive with COVID-19, 12981 (57.8%) recovered without any complications, while 6998 (31.1%) patients were hospitalised, and 2498 (11.1%) patients deceased due to the illness (Table 15).
In the bibliometric analysis of the top 50 most-cited COVID-19 articles, the most cited article was “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China” by Huang C et al., in The Lancet published in 2020. This article has the highest total number of citations (24775) as well as the highest average number of citations per year (8258) among the top 50 most-cited articles.
The Lancet published the greatest number of articles from the top 50 most-cited list with a total of 9 articles, followed by NEJM with 7 articles and JAMA with 4 articles published respectively. Most of the articles (n=48, 96%) were published in the year 2020 with China (n=29, 34.9%), France (n=10, 12.1%) and Belgium (n=10,12.1%) being the top contributing countries.
In this bibliometric analysis, we found that 54.8% of the total patients were males while 45.2% were female patients. An article written by Bwire, it was reported that females were more resistant to Covid-19 infection. This could be attributed to various factors such as sex hormones, higher expression of ACE-2 receptors in men and also difference in the lifestyles.7
The incidence of COVID-19 infection was highest in adults between 26-65 years (63.2%), followed by the adults over 65 years of age (26.8%), and least in 12-25 years age group (9.8%).
Similar findings were reported in a study conducted by Jakhmola S et al, with the highest incidence of Covid-19 infection in the age groups of 20-49 years and above 50 years, and the least in the paediatric age group. This could possibly be due to lesser expression of the coronavirus (ACE-2) receptors in the nasal epithelium in younger age groups, leading to reduced susceptibility to Covid 19 infection.8 Centers for Disease Control and Prevention (CDC) reported the highest incidence of COVID-19 infection among adults above the age of 80 years and in the age group of 18-24 years during 2020.9
In our analysis, the most common clinical features were fever (28.2%), tachycardia (17.9%) and dry cough (13.8%). Other common features included impaired sense of smell (1.8%), impaired taste sensation (1.8%) and headache (1.5%). Similar to the above-mentioned findings, a study by Cascella M et al, reported the most common symptoms in patients to be fever, dry cough and dyspnoea. Other lesser common symptoms included malaise and headache.10 In a study by Mullol J et al., it was concluded that most viral respiratory infections such as COVID-19 are associated with impairment of sense of smell. The incidence of olfactory and gustatory symptoms varies due to the varied methodology used in various studies.11
Of the total patients analysed in our study, 97.8% patients were found to have comorbidities. Of which, hypertension (30.6%), diabetes mellitus (23.1%) and obesity (12.1%) were the commonest comorbidities found in the patients. Other comorbidities included chronic liver disease (0.34%), endocrine disorders (0.24%) and psychiatric disorders (0.06%). In a study by Sanyaolu et al, that the common comorbidities found were hypertension, diabetes mellitus and obesity, which were associated with poorer outcomes in COVID-19 patients.12
Of all the patients analysed in our study, 13.9% of patients developed complications following COVID-19 infection. The common complications seen among the patients were acute kidney injury (22.5%), ARDS (18.3%) and sepsis (11.0%). Other complications included thrombosis (3.6%), acute hepatic injury (2.4%) and arrhythmias (2.0%). In the study by Cascella M et al, it was reported that ARDS was the most common pulmonary complication of COVID-19 while extra-pulmonary complications included AKI, cardiovascular complications and prothrombotic complications.10 Similarly, in another study by Isath A et al., the most common complications reported were respiratory failure, AKI, sepsis and thrombosis.13
In our analysis, 57.8% patients recovered without any complications, while 31.1% were hospitalised, and 11.1% deceased due to the illness. Similar findings were reported in a study by Isath A et al., where 51.4% patients recovered and were discharged home, and the overall inpatient mortality was reported to be 13.2%. Most of the patients with comorbidities were associated with higher number of complications and mortality.13
Analyzing the 50 most-cited articles in COVID-19 and the complications of COVID-19 and assessing their citations-per-year is a valuable approach for clinicians and researchers. It offers a quick overview of the most influential literature and COVID-19 research has evolved over time. Moreover, a detailed review of these articles can uncover the key attributes that make papers highly cited. This insight can be instrumental for authors, offering guidance on creating impactful research in the future. Overall, this method serves as a strategic tool for staying updated and contributing meaningfully to the field of COVID-19 research.
Dryad: Data of top 50 most cited articles about COVID-19 and the complications of COVID-19, https://doi.org/10.5061/dryad.tx95x6b4m. 14
This project contains the following underlying data:
Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
References
1. Khuluq H: The Impact of the COVID-19 Pandemic on Cardiovascular Disease Research: A Bibliometric Analysis. 225: 745-757 Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: bibliometric , big data , machine learning, clinical pharmacy
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 3 (revision) 03 May 24 |
read | read | read |
Version 2 (revision) 16 Apr 24 |
read | ||
Version 1 16 Feb 24 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)